Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

VANCOUVER, July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, which represent at least four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

The phase I clinical trial is an open label, multi-center dose escalation trial evaluating the safety and maximum tolerated dose of a single administration of allogeneic MultiStem cells following an AMI. Enrolled patients received MultiStem delivered via a catheter into the damaged region of the heart 2-5 days following percutaneous coronary intervention (PCI), a standard treatment for heart attack. The study includes patients in three treatment cohorts or dose groups (20 million, 50 million and 100 million cells per patient) and a registry group where patients received only standard of care. Nineteen treated and six registry subjects participated in the study. The trial is being conducted at cardiovascular treatment centers in the United States, including the Cleveland Clinic, Columbia University Medical Center and Henry Ford Health System.

Highlights of the Study:

    -   Administration of MultiStem was found to be well tolerated at all
        dose levels
    -   No clinically significant changes in vital signs, allergic reactions,
        or infusion-related toxicities were associated with MultiStem
        administration
    -   Each dose group showed
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... NASA technologists have hurdled a number of significant ... already revolutionary observing technology originally created for the ... by Principal Investigator Harvey Moseley, a scientist at ... has demonstrated that electrostatically actuated microshutter arrays ... voltage are as functional as the current ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... SEATTLE, May 14 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 2009 ... AM in Room 311 of Building A, Level 3. , ... BIO International Convention, ... 10:40 AM Eastern/4:40 PM Central European/7:40 AM Pacific, ...
... child,s gender with less ethically charged method at Reproductive ... RAMON, Calif., May 13 In response to growing ... of their next child, the Reproductive Science Center of ... it now is offering an alternative gender-selection technique with ...
... Dendreon Corporation (Nasdaq: DNDN ) announced today the ... shares of its common stock, which shares were offered for ... May 8, 2009, Deutsche Bank Securities Inc., acting as sole ... to purchase an additional 1,279,166 shares of common stock at ...
Cached Biology Technology:Gender-Selection Technique Embraced for Hopeful Parents 2Dendreon Announces Closing of Common Stock Offering 2Dendreon Announces Closing of Common Stock Offering 3
(Date:7/30/2014)... potential effects of climate change on the world,s ... wrong factors, according to a new paper by ... University of Queensland, and other organizations. The authors ... missing the point when it comes to climate ... change scientists focus on the "direct" threats of ...
(Date:7/30/2014)... Life Sciences Institute (SALSI), a joint venture between The ... University of Texas Health Science Center at San Antonio, ... Program. The winners, Emily Boice from UTSA and Lei ... for their project titled, "Novel engineered ferritins for tracking ... Boice and Huang,s research is focused on finding a ...
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... San Diego State University researchers will lead a study ... The Guizhou snub-nosed monkey, often called the golden monkey. ... the National Science Foundation, student researchers from SDSU,s departments ... month to the Fanjingshan National Nature Reserve, home to ...
... efficient cars, buildings and domestic appliances to address climate change ... Research at the University of East Anglia. A report ... as much effort is being spent on developing energy supply technologies ... improving the efficiency with which energy is used. The ...
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
Cached Biology News:SDSU researchers to study China's national treasure 2Efforts to mitigate climate change must target energy efficiency 2Efforts to mitigate climate change must target energy efficiency 3New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2
... Zero Blunt TOPO PCR ... fastest and easiest method ... or equal to95%) cloning ... amplified with proofreading thermostable ...
Quartz-Halogen, 100 W, High Intensity...
... The Baculovirus Expression System with ... recombinant pFastBac™ plasmids containing the polyhedrin ... to the baculovirus genome (bacmid DNA) ... E. coli cells. The recombinant bacmid ...
...
Biology Products: